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Abstract: Myostatin is an endogenous, negative regulator of muscle growth determining both muscle fiber number and 
size. The myostatin pathway is conserved across diverse species ranging from zebrafish to humans. Experimental models 
of muscle growth and regeneration have implicated myostatin as an important mediator of catabolic pathways in muscle 
cells. Inhibition of this pathway has emerged as a promising therapy for muscle wasting. Here we discuss the recent de-
velopments and the controversies in myostatin research, focusing on the molecular and cellular mechanisms underlying 
the actions of myostatin on skeletal muscle and the potential therapeutic role of myostatin on muscle-related disorders. 
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MYOSTATIN PROCESSING AND SIGNAL TRANS-
DUCTION 
  Myostatin, also known as GDF8 (growth differentiation 
factor 8), belongs to the transforming growth factor- super-
family of secreted growth and differentiation factors [1]. In 
common with the TGF- family, myostatin is synthesized as 
a precursor protein consisting of a signal sequence, an inac-
tive/inhibitory N-terminal propeptide region and an invariant 
Arg-X-X-Arg proteolytic cleavage site, followed by a C-
terminal domain which dimerizes to form the active/mature 
molecule [1, 2]. After cleavage of the signal sequence and 
proteolytic processing, the mature C-terminal dimer remains 
associated with the propeptide via non-covalent forces creat-
ing a latent complex from which myostatin must be released 
to elicit its biological activity [3-6]. Zimmers and coworkers 
[6] have shown that this latent complex circulates in the 
blood and can be activated by acid treatment. In vitro, latent 
myostatin activation can also been observed upon proteolytic 
degradation of the propeptide by a metalloprotease of the 
bone morphogenetic protein-1/tolloid (BMP1/TLD) family 
[5]. However, the physiological relevance of such a mecha-
nism is not yet established.  
  Although the mechanism of activation of the latent my-
ostatin complex remains to be determined, the bioavalaibility 
and the function of myostatin appear to be dependent of a 
network of protein interactions. Indeed, in addition to the 
propeptide, several other proteins have been identified as 
inhibitory binding proteins of myostatin. Through a number 
of yeast two-hybrid system experiments, four binding part-
ners of myostatin (follistatin, hSGT, Titin cap and decorin) 
have been defined in muscle [7-10] whereas two follistatin 
related proteins FLRG and GASP have be found to be com-
plexed with myostatin in serum [11, 12]. These proteins are 
able to negatively regulate myostatin activation, secretion or 
receptor binding. The effects of these myostatin binding pro- 
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teins are summarized in Table 1 [2, 7-17]. Interestingly, 
three of these proteins, the myostatin propeptide, follistatin 
and FLRG have been shown to be capable of increasing 
muscle mass when expressed as a transgene in skeletal mus-
cle of wild type mice (Table 1) [13-15]; a phenotype compa-
rable to those seen in myostatin knock-out mice [1]. How-
ever, the increases in muscle mass in the follistatin transgen-
ics are significantly greater than the increases in the my-
ostatin null mice [13]. Furthermore, when the follistatin 
transgene is combined with a myostatin null mutation, the 
two phenotypes appear additive as the increase in muscle 
mass is quadrupled [15]. Such findings indicate that other 
ligands cooperate with myostatin to control muscle growth 
and underscore the need to determine the identity of such 
ligands to elaborate the most effective strategy for manipu-
lating this signalling pathway.  
  Although not fully characterized, the signalling pathway 
and mechanism of myostatin action appear similar to those 
exhibited by members of the TGF- superfamily. The mature 
myostatin peptide binds to one of the two activin type II re-
ceptors (ActRIIB to a greater degree than ActRIIA), which 
recruits, phosphorylates and thereby activates the activin 
type I receptor propagating signals along the Smad pathway 
[13, 18]. Myostatin acts through the receptor-associated pro-
teins Smad2 and Smad3 [13, 19, 20]. Phosphorylated Smad2 
and Smad3 form heterodimeric complex with the common 
mediator Smad4. These activated smad proteins function as 
the key intracellular mediators of signalling for myostatin as 
they translocate into the nucleus, and activate the transcrip-
tion of the target genes through interaction with DNA and 
other nuclear factors [21, 22]. Interestingly, the inhibitory 
Smad7 protein is implicated in myostatin signalling. My-
ostatin signalling induces the inhibitory Smad7 protein 
which in turn abrogates the canonical myostatin signalling 
pathway, establishing a negative feedback mechanism [23, 
24].  
 Like  TGF- family members, myostatin also induces the 
activation of various MAPK cascades. Philip and coworkers 
[25] established that myostatin activates the p38 MAPK 
through the TAK1-MKK6 pathway, independently from 416    Current Genomics, 2007, Vol. 8, No. 7  Carnac et al. 
SMAD activation. The authors also show that the p38 MAPK 
functions cooperatively in myostatin-induced, SMAD-
mediated transcription. It is however unclear how these two 
pathways - the Smad-mediated pathway and - the TAK1-p38 
MAPK pathway communicate but the authors suggest that 
the type I receptor might be a common upstream signalling 
component for these pathways [25]. Recent evidence from 
Yang and co-workers [26] described the involvement of 
Erk1/2 MAPK cascade in myostatin signalling. Their results 
suggest that myostatin is capable of activating Erk1/2 MAPK 
pathway through Ras, a relative upstream intracellular regu-
lator of Erk1/2. Work by this same group has also demon-
strated the role of the PI3K/Akt/GSK-3 pathway in my-
ostatin signalling transduction during myogenesis [27] (see 
below). Finally, another subfamily of the MAPK superfa-
mily, the c-Jun N-terminal kinase (JNK) signalling pathway, 
is also involved in myostatin signalling [28].  
  Taken together, these results demonstrate that myostatin 
signalling can recruit various intracellular signalling cas-
cades and suggest that myostatin signalling might be regu-
lated by cross-talks with tyrosine kinases-linked growth re-
ceptor signalling pathways and/or other pathways that re-
main to be elucidated.  
MYOSTATIN, A FACTOR CONTROLLING MUSCLE 
SIZE 
  Muscle size depends on fiber number and fiber size. The 
number of fibers is usually set during development while 
their size continously adapts during the entire lifetime de-
pending on activity, nutrition, diseases and aging. In the last 
decade myostatin has emerged as a key maintenance regula-
tor of muscle mass. The role of myostatin in muscle comes 
from the phenotype of myostatin-deficient animals. My-
ostatin was first found to regulate muscle mass in mice from 
which the gene encoding myostatin has been knocked-out. 
The resulting “mighty mice” displayed muscle overgrowth 
due to both hyperplasia (increased number of muscle fibers) 
and hypertrophy (increased size of individual muscle fibers) 
[1]. These effects on muscle mass are persistent throughout 
the life of the animals. Subsequently, the fundamental role of 
myostatin in adult muscle homeostasis is demonstrated by 
the increased muscle mass of mice having a postnatal dele-
tion of the myostatin gene or of adult mice injected with 
various inhibitors of myostatin [5, 29-31]. Therefore, my-
ostatin appears to act at two major points during muscle de-
velopment; at the level of fiber number during muscle em-
bryogenesis and the level of fiber growth in the adult.  
  The function of myostatin appears to have been con-
served accross diverse species as indicated by the doubling 
of muscle mass in cattle, sheep, dog and human carrying 
natural mutations in the myostatin gene [1, 32-36]. In sup-
port of this, myostatin sequence is highly conserved through 
evolution, among species ranging from zebrafish to humans 
[1]. Thus, the discovery that myostatin acts as a negative 
regulator of muscle growth has led to intense scrutiny of the 
possibility that myostatin inhibition might be useful in treat-
ment of muscle-wasting-related disorders. Accordingly, ge-
netic inhibition of myostatin function or myostatin blockade 
by several agents (including myostatin antibodies, myostatin 
propeptide, follistatin-related proteins, soluble type II my-
ostatin receptor) have been shown to be effective in increas-
ing muscle mass and reducing disease severity in the mdx 
mouse model of Duchenne muscular dystrophy, in the 
caveolin 3 deficient model of limb-girdle muscular dystro-
phy 1C (LGMD1C) and in two rodent models of amyotro-
phic lateral sclerosis [19, 37-40]. Although myostatin does 
not correct the primary defects in muscle dystrophy, it can 
lessen the severity of the disease phenotype. In contrast, loss 
of myostatin activity in the dy
w/dy
w mouse model of laminin-
deficient congenital muscular dystrophy, did not ameliorate 
Table 1.  Summary of Data on the Effects of the Myostatin Binding Proteins 
  In Vitro  Animal   Human 
Myostatin  
propeptide 
Antagonizes myostatin biological activity  
by inhibiting myostatin receptor binding [2] 
Overexpression of propeptide associated  
with increased muscle mass [13, 14] 
 
FLRG  Inhibits myostatin activity in signalling  
assays, maintains myostatin latency [11] 
Overexpression of FLRG associated  
with increased muscle mass [15] 
 
GASP 1  Inhibits myostatin activity in signalling  
assays, maintains myostatin latency [12] 
  
hSGT  Inhibits myostatin activity in signalling  
assays [10] 
  
Titin-cap  
(telethonin) 
Myoblasts overexpressing titin-cap associated  
with increased myoblast proliferation, regulates  
myostatin secretion [9] 
  Lack of functional Titin-cap protein is  
responsible for a rare limb girdle  
muscular Dystrophy type 2G [17] 
Follistatin  Inhibits myostatin receptor binding, antagonizes 
myostatin inhibition of myogenesis [7] 
Overexpression of follistatin associated with  
increased muscle mass [13]; Loss of Follistatin  
associated with reduced muscle mass [16] 
 
Decorin   Blocks the inhibitory effect of myostatin on 
proliferation of muscle cells [8] 
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the muscle pathology but increased postnatal lethality [41]. 
With respect to the therapeutic benefit of myostatin inhibi-
tion, Parsons et al. [42] reported that elimination of my-
ostatin can improve the dystrophic phenotype in mice nul-
lizygous for -sarcoglycan (scgd
-/-) (a model of human limb-
girdle muscular dystrophy referred as LGMD2F). However, 
this effect is obtained only in young dystrophic mice but not 
in older ones. In addition, their results also showed that the 
effectiveness of myostatin blockade could be dependent on 
specific muscle groups studied. Taken together these studies 
indicate that myostatin inhibition may not be beneficial in all 
dystrophic contexts. This is supported by data showing that 
AAV-mediated delivery of a mutated myostatin propeptide 
in the muscles of animal models of two limb-girdle muscular 
dystrophies (LGMD2A caused by mutations in the calpain 
gene and LGMD2D caused by mutations in the -
sarcoglycan gene) leads to different outcomes: it ameliorates 
calpain 3 but not -sarcoglycan deficiency [43]. Therefore, it 
will be important for investigating the myopathies that are 
susceptible to myostatin antagonism, and, conversely, for 
identifying the stages of the disease at which the myostatin 
blockade is operative. 
  There is also controversy about the potential improve-
ment of muscle strength in response to myostatin inhibition. 
Using front paw grip strength, several studies have reported 
an improvement of force generation in myostatin knock-out 
mice as well as in wild type mice treated with antibody anti-
myostatin or immunized with a DNA vaccine against my-
ostatin [31, 44, 45]. This measurement is considered very 
crude and functional measurements on single fibres would be 
more informative. Studies examining the effects of myostatin 
deficiency on the contractile properties of dystrophic mus-
cles have reported disparate results. Treatment with anti-
myostatin antibody led to an increase in the maximal tetanic 
force generation, but when expressed as a function of muscle 
size specific force generation was decreased, whereas an 
improvement both in maximal and specific tetanic force is 
obtained when the propetide approach is used [19, 40]. 
These results obtained by the group of Bogdanovitch suggest 
that the effect on muscle force might be dependent upon the 
experimental approach. In addition, work from two inde-
pendent laboratories has reported a decrease in force genera-
tion of muscles from myostatin null mutants [46, 47]. Earlier 
work from Mendias et al. [47] showed a decrease in specific 
force for edl muscle in myostatin knock-out mice whereas 
specific force of soleus muscle is unaffected. Likewise, Am-
thor and coworkers [46] reported that despite an increase in 
muscle mass in myostatin knock-out mice they observed no 
increase in maximal muscle force, but that specific muscle 
force was severely decreased both in edl and soleus muscles. 
Their results also revealed that such decrease in specific 
force is associated with mitochondrial depletion and loss of 
oxydative characteristics of skeletal muscle. Based on these 
observations it appears that excessive muscle growth follow-
ing deficiency in myostatin compromises force generation. 
These results also suggest that muscle hypertrophy due to 
myostatin absence may in fact not be beneficial to skeletal 
muscle. In conclusion, these complexities underscore the 
importance of further studies of the effects of myostatin 
blockade before the results of experiments using antagonist 
drugs can be interpreted clearly.  
MYOSTATIN AND SATELLITE CELLS 
  Growth and repair of skeletal muscle are carried out by a 
group of quiescent muscle stem cells known as satellite cells. 
In response to tissue damage or hypertrophic stimuli, these 
cells are activated and will proliferate and differentiate [48-
50]. However, a small proportion of these activated satellite 
cells does not differentiate, returns to quiescence to maintain 
the pool of satellite cells on the muscle fibers (Fig. 1). Inter-
estingly, myostatin has been proposed to be a key signalling 
molecule that signals the quiescence of satellite cells and 
their progeny, the myoblasts. Direct analysis of satellite cells 
in myostatin mutant mice has shown an increased number of 
satellite cells per single myofiber and a higher proportion of 
activated satellite cells compared to wild-type mice [51]. In 
addition, satellite cells isolated from myostatin null mice 
proliferate and differentiate more rapidly than satellite cells 
isolated from wild-type mice. These results suggest that my-
ostatin maintains satellite cells in a quiescent state and that 
during regeneration or muscle growth these muscle progeni-
tor cells could be reactivated upon release from the inhibi-
tory effect of myostatin. In line with this notion, several 
groups have attempted to elucidate the intervention of my-
ostatin in muscle regeneration after injury or in degenerative 
diseases [19, 45, 52]. It has been demonstrated that regenera-
tion after injury in myostatin null muscle is improved com-
pared to the wild-type controls. Recent evidence from 
McCroskery and coworkers [52] suggests that myostatin 
negatively regulates muscle regeneration not only by con-
trolling satellite cell activation but also by regulating the 
migration of myoblasts and macrophages to the site of in-
jury. Inhibition of myostatin in mdx mice that are known to 
have cycles of degeneration also reveals evidence for im-
proved muscle regeneration in lack of myostatin [45]. The 
muscles of these mice show signs of persistent degeneration 
and regeneration, but they are bigger and exhibit an im-
provement of their histological features, such as decreased 
fibrosis compared to muscles of mdx mice [45]. Although the 
mechanism by which myostatin regulates muscle regenera-
tion has yet to be clarified, these findings highlight the im-
portance of myostatin in the process of muscle repair both 
after injury or in degenerative diseases. The importance of 
myostatin action in muscle repair is also substantiated by 
recent results of Sirriet et al. [53] showing that a short-term 
blockade of myostatin function significantly enhances mus-
cle regeneration in aged mice after injury and during sarco-
penia. This antagonism of myostatin led to satellite cell acti-
vation, increased expression of myogenic cell markers and 
greater myoblast and macrophage cell migration. These find-
ings support earlier results showing that muscles of aged 
myostatin null mice continue to regenerate robustly from 
both chronic and acute injury [45, 54]. Therefore, the inhibi-
tion of myostatin appears protective against “normal” loss of 
muscle mass during aging. These result suggest that the ab-
sence of myostatin could also alleviate sarcopenia through 
the activation of satellite cells. In this respect, high serum 
concentrations of myostatin-immunoreactive protein have 
been found in older women and men with muscle wasting 
(sarcopenia) however, so far the role of myostatin in aging-
induced sarcopenia has not been determined.  
  How does the myostatin signalling act on satellite cell 
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myostatin is able to arrest the cell cycle at the G1 phase of 
cultured myoblasts including C2C12 myoblasts, primary 
bovine myoblats and mouse satellite cells, and thereby in-
duces inhibition of proliferation and differentiation [3, 18, 
51, 55]. It has been reported that myostatin can affect one or 
more of the cell cycle control proteins: the anti-proliferative 
action of myostatin is associated with an up-regulation of 
p21 (cyclin-dependent kinase inhibitor) and subsequently 
decreases in the levels of both cyclin-dependent kinases 
(Cdk2 and Cdk4) and phosphorylated Rb (retinoblastome 
protein) [3, 18, 21, 51] (Fig. 1). Although the mechanism 
underlying the anti-proliferative action of myostatin has yet 
to be elucidated, but one possibility presented by Yang et al. 
[27] indicates that myostatin down-regulates Cdk4 activity 
via  promotion of degradation of cyclin D1, an important 
component of the cell cycle machinery. Their results suggest 
that myostatin is capable of stimulating Akt inhibition, GSK-
3 activation and cyclin D1 destabilization, and that this 
process is dependent upon the activin receptor IIB, but not 
Smad3.  
  The inhibitory effect of myostatin on differentiation is 
associated with down regulation of the myogenic differentia-
tion factors MyoD, Myf5 and myogenin [21]. Therefore the 
function of myostatin appears to derive from its inhibitory 
effects on the proliferation and differentiation of muscle 
cells.  
  Myostatin also inhibits satellite cell activation and self 
renewal [51]. Although the mechanism behind this function 
in satellite cell is not known, recent evidence from McFar-
lane et al. [56] suggests that myostatin signals via a Pax7-
dependent mechanism to regulate satellite self-renewal (Fig. 
1).  
ROLE OF MYOSTATIN IN MUSCLE ADAPTATION 
  The control of muscle mass is determined by a dynamic 
balance of anabolic and catabolic processes. Muscle hyper-
trophy is characterized by an increased in diameter and in 
total protein content of fibres and occurs as a result of an 
enhanced rate of protein synthesis while muscle atrophy in-
duced by a decrease in activity and load or by catabolic loss 
of muscle mass is a decrease in the size of pre-existing mus-
cle fibers, resulting from a dramatic increase in protein deg-
radation and turn-over. A wealth of data supports that my-
ostatin functions by inducing muscle atrophy. For example, 
elevated myostatin expression correlates with several set-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The potential functions of myostatin in regulating satellite cells. Growth and repair of adult skeletal muscle require the action of 
a population of normally quiescent myogenic precursors called satellite cells (SC) which reside between the basal lamina and the plasma 
membrane of the myofibres. In response to muscle injury or increased muscle tension, these cells become activated, start proliferating and 
are responsible for the repair of damaged muscle fibres and the growth of muscle fibres. Importantly, a proportion of the progeny of the acti-
vated satellite cells does not differentiate, but withdraws from the cell cycle to replace the activated satellite cell used, in a process of self-
renewal. Myostatin negatively regulates satellite cell activation and self-renewal. A possible function is that Myostatin inhibits/prevents the 
progression of myoblats from the G1 to S phase of the cell cycle through up-regulation of p21 and subsequent inhibition of Cdk2 activity, 
thus maintaining the quiescence of satellite cells. Another function is that myostatin inhibits the self-renewal of the satellite cell population 
through down-regulation of Pax7. Myostatin in the Pathophysiology of Skeletal Muscle  Current Genomics, 2007, Vol. 8, No. 7    419 
tings of muscle loss including prolonged bed rest in young 
men [57], chronic disuse atrophy in older patients [58] and 
age-related muscle wasting (sarcopenia) [59]. Likewise, in-
creased myostatin mRNA and protein expression are ob-
served in a rat cirrhosis model that causes muscle atrophy 
[60]. 
  Relevant to muscle wasting diseases, it has been shown 
that inhibition of myostatin rescued the muscular atrophy of 
caveolin-3-deficient mice [37]. The inhibition of myostatin 
also protects against muscle atrophy due to glucocorticoid 
treatment [61] and the effect of glutamine on prevention of 
glucocorticoid-induced skeletal muscle atrophy is associated 
with myostatin suppression [62]. Thus, induction of my-
ostatin could explain the decreased protein synthesis ob-
served in several settings of muscle atrophy. The crucial role 
of myostatin in inducing muscle atrophy is highlighted by 
the work from Zimmers et al. [6] demonstrating that admini-
stration of myostatin in vivo to adult mice produces the signs 
and symptoms characteristic of the muscle wasting syn-
drome, cachexia. In addition, the muscle wasting observed in 
these mice can be partially reversed by systemic delivery of 
the myostatin propeptide or follistatin in the mice indicating 
that the observed muscle wasting was caused by excess my-
ostatin. Similarly, ectopic expression of myostatin through 
gene electrotransfer of a myostatin expression vector induces 
atrophy of skeletal adult muscle associated with decreased 
muscle gene expression [63]. The efforts of several laborato-
ries have shed new insight into how myostatin induces mus-
cle atrophy. Earlier work from Taylor et al. [55] showed that 
myostatin inhibited the proliferation as well as protein syn-
thesis in C2C12 myoblasts and myotubes. Recently, McFar-
lane et al. [64] demonstrated that myostatin induces cachexia 
by activating the ubiquitin proteolytic system through a 
FOXO1-dependent mechanism. Importantly, it has been 
shown that FOXO1 also upregulates the expression of my-
ostatin [65, 66]. Therefore, a positive feedback mechanism 
between these two pathways may amplify the atrophic re-
sponse. While the above findings are undisputed it should be 
noted that these studies have involved overexpression of 
constitutively active myostatin which is likely exceed the 
strength of a physiological stimulus, resulting in possible 
loss of specificity. Future studies are therefore required to 
define whether chronic activation of myostatin is correlated 
with cancer cachexia.  
  In contrast to the above findings, several independant 
studies have reported that myostatin might not be required in 
some types of muscle atrophy. Indeed, myostatin levels are 
not increased in muscle atrophy due to denervation or 
hindlimb suspension [67, 68]. Unexpectedly, the myostatin 
deficient mice lost more muscle mass than normal controls 
after hindlimb suspension [69]. These data indicate that ab-
sence of myostatin does not protect against muscle atrophy 
and also suggest that the action of myostatin might be to 
inhibit muscle hypertrophy rather than induce atrophy. These 
results also demonstrate that myostatin is likely not the pri-
mary cause of muscle atrophy. In conclusion, despite this 
progress in our understanding of the role of myostatin in 
muscle atrophy, mechanisms involved in regulation and ac-
tions of myostatin in all forms of muscle atrophy remain to 
be clarified.  
  Another question that remains to be investigated is 
whether myostatin also plays a role in inactivating hypertro-
phic pathways. There is substantial evidence to suggest that 
myostatin could be connected with pathways regulating hy-
pertrophy. The recent work of McFarlane [64] has shown 
that the protein kinase Akt is a target for myostatin action. 
Myostatin negatively regulates Akt by dephosphorylation of 
serine 473 which induces Foxo transcription factors and ac-
tivates the expression of components of the ubiquitin-
proteasome pathway such as MAFbx, to degrade muscle 
protein. Akt has been shown to be activated during hypertro-
phy, and it is a known upstream activator of protein synthe-
sis [70, 71]. Therefore it appears possible that myostatin may 
also counter hypertrophic signalling through inactivation of 
Akt leading to decreased protein synthesis, but this has yet to 
be tested. Several data exist showing that myostatin appears 
to be sensitive to hypertrophic signals. For example, the ana-
bolic agent GH decreased myostatin expression in muscles 
of GH-deficient adults [72] and androgens negatively regu-
late myostatin expression in an androgen-dependent skeletal 
muscle [73]. A similar down regulation of myostatin is ob-
served in mouse muscles subjected to functional overload 
[74] and in human with strength-training exercise [75, 76]. 
Indeed, myostatin seems to play a role in modulating muscle 
mass in response of anabolic stimuli. These findings raise the 
question whether a negative feedback-loop exists between 
myostatin and hypertrophic pathways. Collectively these 
data suggest that atrophy and hypertrophy pathways could 
communicate with each other via myostatin. However, future 
researches should be focused on exploring how myostatin is 
connected with the cellular signalling pathways regulating 
the anabolic and catabolic responses in muscle.  
CONCLUDING REMARKS AND KEY UNAN-
SWERED QUESTIONS 
  Increasingly, research into the mechanisms by which 
myostatin controls muscle mass has revealed both new com-
ponents of this signalling pathway and the participation of 
parallel pathways in the mediation of myostatin signal. It has 
been established that myostatin signalling can recruit various 
intracellular signalling cascades, however it remains unclear 
how these pathways are intercalated. With respect to new 
components of myostatin signalling pathway, decorin, a 
component of the extra-cellular matrix (ECM) has been dis-
covered recently that binds myostatin and modulates its ac-
tivity. This provides another means by which myostatin sig-
nalling can be controlled and raises the question of a poten-
tial link between myostatin activity and ECM integrity. Also, 
the demonstration that other TGF- related ligands cooperate 
with myostatin to suppress muscle growth makes the search 
for manipulating TGF- signalling pathways attractive.  
  It is well documented that myostatin is important for 
proper development and homeostasis of adult musculature. 
In this line, the link between myostatin and the Akt/Foxo 
pathway may account, at least in part, for observations that 
support a role for myostatin in breaking or promoting muscle 
wasting. It will be challenging and informative to determine 
whether myostatin can also interfere with anabolic pathways. 
  In the last decade, the blockade of myostatin has been 
represented an ideal tool to attenuate muscle wasting related 420    Current Genomics, 2007, Vol. 8, No. 7  Carnac et al. 
to diseases, and there is a multi center clinical trial on adult 
patients with muscular dystrophy underway. The beneficial 
effects of loss of myostatin activity reside in enhancing mus-
cle mass, however, there is also evidence that this increased 
muscle mass may in fact not be beneficial to skeletal muscle 
function. Indeed, Amthor et al. [46], recently reported that 
despite an increase in size the muscles of myostatin knock-
out mice are weaker and show a predominance of fast glyco-
lytic fibers, a loss in mitochondrial enzymes and a mito-
chondrial depletion. Further research will be necessary to 
balance the benefits and risks of myostatin blockade in the 
development of a beneficial therapy. It will be particularly 
important to elucidate the mechanisms of muscle metabolism 
that are affected by myostatin inhibition.  
ACKNOWLEDGEMENTS 
  Work in the authors’s laboratories is supported by grants 
from the Institut National de la Recherche Agronomique 
(INRA), the INSERM, and the Association Française contre 
les Myopathies (AFM: Grants N° 12136 and N°13000). 
ABBREVIATIONS 
TGF-  =  Transforming growth factor- 
GDF8  =  Growth differentiation factor 8 
BMP-1/ 
TLD family  =  Bone morphogenetic protein-1/tolloid fam-
ily of proteinases 
FLRG  =  Follistatin like related gene 
GASP  =  Growth and differentiation factor-
associated serum protein 
SMADs  =  Family of transcription factors that mediate 
TGF- signals. The term SMAD is derived 
from the founding members of this family, 
the Drosophila protein MAD (Mothers 
Against Decapentaplegic) and the 
Caenorhabditis elegans protein SMA 
(Small body size). 
MAPK  =  Mitogen-activated protein kinase 
AIDS =  Acquired  immuno-deficiency  syndrome 
DMD =  Duchenne  Muscular  Dystrophy 
ActRIIB  =  Activin type II B receptor 
GH =  Growth  hormone 
MAFbx =  Muscle  atrophy  F-box 
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